Advanced Glycation End Products and Psoriasis
Vaccines · 08.03.2023 · 11 (3) · 617
DOI: 10.3390/vaccines11030617 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 08.03.2023. Verfasst von Martina Maurelli und 2 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, Italy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Advanced glycation end products (AGEs) are biologically active compounds formed physiologically throughout a sequence of chemical reactions, to generate highly oxidant-reactive aldehydes that combine covalently to proteins. They accumulate slowly in tissues during ageing but also in metabolic and selected inflammatory disorders. Accumulation of AGEs occurs more rapidly and intensely in the skin and serum of patients with type 2 diabetes, obesity, cardiovascular diseases, chronic renal insufficiency, and non-alcoholic fatty liver disease and also in the skin of patients with psoriasis. All of the above conditions are intimately associated with psoriasis. Interaction of AGEs with their receptors (RAGEs) stimulates cellular signaling with the formation of reactive oxygen species and activation of nuclear factor kappa light chain enhancer of activated B (NF-kB), which is a key regulator in the expression of inflammatory mediators and the production of oxidative stress. Thus, AGEs may play an interesting pathogenic role in the intersection of inflammatory and metabolic diseases, may represent a biomarker of inflammation and a potential target for novel therapeutic strategies. This is a narrative review with the objective to summarize current evidence on the role of AGEs in psoriasis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, Italy.
ORCID-Profile: Martina Maurelli, Paolo Gisondi, Giampiero Girolomoni
Zitieren
APA
Maurelli, M., Gisondi, P., & Girolomoni, G. (2023). Advanced Glycation End Products and Psoriasis. Vaccines, 11(3), 617. https://doi.org/10.3390/vaccines11030617
Vancouver
Maurelli M, Gisondi P, Girolomoni G. Advanced Glycation End Products and Psoriasis. Vaccines. 2023;11(3):617. doi:10.3390/vaccines11030617
BibTeX
@article{Maurelli2023,
author = {Maurelli, Martina and Gisondi, Paolo and Girolomoni, Giampiero},
title = {Advanced Glycation End Products and Psoriasis},
journal = {Vaccines},
year = {2023},
volume = {11},
number = {3},
pages = {617},
doi = {10.3390/vaccines11030617}
}
EUVIMED